Cargando…

Informing radiotherapy decisions in stage I/IIa Hodgkin lymphoma: modeling life expectancy using radiation dosimetry

In recent randomized trials, omitting consolidative radiotherapy (RT) in early-stage Hodgkin lymphoma (ESHL) increased relapses. However, decades of follow-up are required to observe whether lower initial disease control is compensated by reduced risk of late effects. Extrapolation beyond trial foll...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jones, David A., Candio, Paolo, Shakir, Rebecca, Ntentas, Georgios, Ramroth, Johanna, Gray, Alastair M., Cutter, David J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Lymphoid Neoplasia
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945315/ https://www.ncbi.nlm.nih.gov/pubmed/34872107 http://dx.doi.org/10.1182/bloodadvances.2021006254

Ejemplares similares

P095: Personalised Modelling of Quality-Adjusted Survival Benefit and Cost-Effectiveness of using Proton Beam Therapy inthe Treatment of Intermediate-Stage Hodgkin Lymphoma in England
por: Jones, David, et al.
Publicado: (2022)

A significant proportion of classic Hodgkin lymphoma recurrences represents clonally unrelated second primary lymphoma
por: van Bladel, Diede A. G., et al.
Publicado: (2023)

Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma
por: Forlenza, Christopher J., et al.
Publicado: (2021)

Therapy Selection for Hodgkin Lymphoma in Sickle Cell Disease: balancing risks and benefits
por: Fraley, Claire E., et al.
Publicado: (2022)

Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients
por: Karihtala, Kristiina, et al.
Publicado: (2022)

Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma
por: Forlenza, Christopher J., et al.
Publicado: (2023)

Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort
por: Bowers, Jackson T., et al.
Publicado: (2023)

International validation of a health-related quality-of-life questionnaire for Hodgkin lymphoma: the EORTC QLQ-HL27
por: Oerlemans, Simone, et al.
Publicado: (2023)

P077: Predicting radiotherapy dose to the heart and the risk of radiation-related cardiac toxicity for Hodgkin lymphoma patients, using pre-chemotherapy PET-CT scans
por: Shakir, Rebecca, et al.
Publicado: (2022)

Incidence and time trends of second primary malignancies after non-Hodgkin lymphoma: a Swedish population-based study
por: Joelsson, Joel, et al.
Publicado: (2022)

Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma
por: Little, Jessica S., et al.
Publicado: (2022)

Prognostic model using (18)F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma
por: Driessen, Julia, et al.
Publicado: (2023)

JAK/STAT blockade reverses the malignant phenotype of Hodgkin and Reed-Sternberg cells
por: Fernández, Sara, et al.
Publicado: (2022)

Retrospective characterization of nodal marginal zone lymphoma
por: Stuver, Robert, et al.
Publicado: (2023)

T022: Sharing decisions regarding radiotherapy for Hodgkin lymphoma: a qualitative study of the experiences of patients and clinicians in the UK
por: Shakir, Rebecca, et al.
Publicado: (2022)

Comparative outcomes for mature T-cell and NK/T-cell lymphomas in people with and without HIV and to AIDS-defining lymphomas
por: Koh, Min Jung, et al.
Publicado: (2022)

Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2023)

Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
por: Castellino, Alessia, et al.
Publicado: (2022)

Genetic subgroups inform on pathobiology in adult and pediatric Burkitt lymphoma
por: Thomas, Nicole, et al.
Publicado: (2023)

The molecular hallmarks of primary and secondary vitreoretinal lymphoma
por: Bonzheim, Irina, et al.
Publicado: (2022)

Genetic subdivisions of follicular lymphoma defined by distinct coding and noncoding mutation patterns
por: Dreval, Kostiantyn, et al.
Publicado: (2023)

SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma
por: Wrench, David, et al.
Publicado: (2011)

Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2022)

Genomic characterization of lymphomas in patients with inborn errors of immunity
por: Ye, Xiaofei, et al.
Publicado: (2022)

Unraveling the genetics of transformed splenic marginal zone lymphoma
por: Grau, Marta, et al.
Publicado: (2023)

HGAL inhibits lymphoma dissemination by interacting with multiple cytoskeletal proteins
por: Jiang, Xiaoyu, et al.
Publicado: (2021)

Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303
por: Russler-Germain, David A., et al.
Publicado: (2023)

Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV
por: Los-de Vries, G. Tjitske, et al.
Publicado: (2022)

Aberrant MYCN expression drives oncogenic hijacking of EZH2 as a transcriptional activator in peripheral T-cell lymphoma
por: Vanden Bempt, Marlies, et al.
Publicado: (2022)

Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma
por: Lakhotia, Rahul, et al.
Publicado: (2022)

Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma
por: Narkhede, Mayur, et al.
Publicado: (2022)

Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma
por: Bewicke-Copley, Findlay, et al.
Publicado: (2022)

Clonotype pattern in T-cell lymphomas map the cell of origin to immature lymphoid precursors
por: Iyer, Aishwarya, et al.
Publicado: (2022)

Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers
por: Rodríguez, Marta, et al.
Publicado: (2021)

Proinflammatory microenvironment promotes lymphoma progression in mice with high megakaryocyte and TPO levels
por: Au, Amanda E., et al.
Publicado: (2022)

Predictors of survival in patients with MALT lymphoma: a retrospective, case-control study
por: Qi, Shunan, et al.
Publicado: (2022)

A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma
por: Sawalha, Yazeed, et al.
Publicado: (2023)

Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy
por: Rodríguez-Sevilla, Juan Jose, et al.
Publicado: (2022)

Clonal germinal center B cells function as a niche for T-cell lymphoma
por: Fujisawa, Manabu, et al.
Publicado: (2022)

Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma
por: Burack, W. Richard, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_odanhahm654v5o9021c8g27to2